Last updated on May 2019

A Phase 2b Study of NGM282 in Participants With Histologically Confirmed Nonalcoholic Steatohepatitis (NASH)

Brief description of study

This is a multi-center evaluation of NGM282 in a randomized, double-blind, placebo-controlled study administered for 24 weeks in participants with histologically confirmed NASH and F2/F3 Fibrosis.

Clinical Study Identifier: NCT03912532

Find a site near you

Start Over

NGM Clinical Study Site

Hermitage, TN United States
  Connect »